Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613000110785
Ethics application status
Not yet submitted
Date submitted
24/01/2013
Date registered
30/01/2013
Date last updated
30/01/2013
Type of registration
Prospectively registered

Titles & IDs
Public title
Investigation of respiratory-related tumour motion in liver cancer patients undergoing stereotactic body radiotherapy (SBRT) using audiovisual (AV) biofeedback
Scientific title
Evaluating the improvement in reproducibility of respiratory-related tumour motion (via fiducial maker surrogacy) for 30 liver cancer patients by assessing the potential clinical benefit of the audiovisual (AV) biofeedback respiratory guidance system.
Secondary ID [1] 281803 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Liver cancer 288192 0
Motion management 288193 0
Condition category
Condition code
Cancer 288557 288557 0 0
Liver

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Audiovisual biofeedback is a non-invasive, interactive respiratory guide designed to significantly reduce respiratory irregularities in order to maximize the accuracy of treatment planning as well as the efficiency of treatment delivery.
The AV biofeedback system is comprised of audio-visual goggles that the patient wears to receive their audio and visual guiding prompts. The real-time respiratory input is provided by an infra-red camera tracking the motion of a marker positioned on the patient's abdomen. The AV biofeedback system will be implemented during two CBCT scans. By breathing with the guidance of AV biofeedback participants will wear the goggles and follow the audio and visual prompts as best they can. By breathing without the guidance of AV biofeedback, the participant does not wear the goggles, but their respiration motion is still monitored.
As a part of their clinical treatment plan, the patients will already be having 18 CBCT scans; by participating in this study, they will have only two additional CBCT scans.
The patients specifically undergoing SBRT are chosen because they will already have fiducial markers implanted about their liver tumours. SBRT does not form a part of this study. This AV biofeedback study will be conducted during their treatment planning phase when they are receiving numerous CBCT scans.
Each study session will take a total of 1 hour inclusive of setting and packing up the AV biofeedback system in addition to the CBCT scans, but it may be completed in less time than this. After each session the patient will be asked to complete a questionnaire regarding the AV biofeedback system; each questionnaire is designed to only take 2 minutes to complete.
The additional 2 CBCT scans for this study will be performed one after the other within the one hour study session. There is one study session for each patient, the frequency of study sessions will be dependent on the recruitment rate of liver cancer patients at RPA Hospital.
The study session will be booked during the patient's treatment planning phase based on the availability of the patient's physician, radiation oncologist and medical physics staff.
Intervention code [1] 286394 0
Treatment: Devices
Comparator / control treatment
Uncontrolled
Control group
Uncontrolled

Outcomes
Primary outcome [1] 288716 0
Evaluate improvement in the reproducibility of respiratory-related tumour motion for liver cancer patients with the AV biofeedback system.
Respiratory motion of external marker and internal fiducial markers will be assessed via a respiratory displacement and frequency analysis. The regularity metric root mean square error (RMSE) of displacement and period will be used to quantify respiratory reproducibility. Numerous studies investigating respiratory motion have used this metric to measure respiratory reproducibility.
External respiratory data will be attained from the real-time position management (RPM) system, which is frequently used clinically and is already installed within the facility. The RPM system is an infra-red camera monitoring the motion of a marker block positioned on the patient's abdomen.
Internal fiducial marker motion will be obtained from the CBCT images in a post-acquisition analysis.
Timepoint [1] 288716 0
Two years after first recruitment
Secondary outcome [1] 300816 0
Assess the clinical benefit of AV biofeedback based on:
(1) The proportion of patients benefiting from AV biofeedback will be obtained. The metric used to quantify respiratory reproducibility: RMSE will be used for this. A lower value of RMSE (in displacement or period) is indicative of more reproducible respiratory motion. The proportion of patients will be determined from the number of patients for whom their RMSE value was lower for AV biofeedback-guided respiration.
(2) Quantification of the improvement in dose distributions and treatment margins with and without AV biofeedback by reconstructing the delivered dose using a method developed for liver SBRT. The reconstruction of the delivered dose will be done using the dose reconstruction method of Poulsen, et al (Med Phys, 2012). This dose reconstruction method incorporates the motion information of the target and is compatible with a number of treatment planning systems including Eclipse, Varian Systems (available at Royal Prince Alfred Hospital).
(3) Quantification of the reduction in 4D CT errors with/without AV biofeedback by programming the Quasar phantom with the audiovisual and free-breathing traces.
The Quasar phantom is commonly used in clinical quality assurance tests; it is a phantom that can be programmed to simulate a previously acquired respiratory signal. The respiratory signals that will be acquired in this study will then be used as input for the Quasar phantom to simulate during 4D CT (rather than the lower image quality: CBCT) to determine whether the AV biofeedback improves 4D CT image quality.
(4) Reconstruction of CBCT images into 4D CBCT using the respiratory signal and compare the image quality with/without AV biofeedback. The acquired CBCT images will be compiled into a 4D "movie" of the region of interest (i.e. liver and fiducial markers). The clarity of the images and real-time motion of the fiducial markers will be compared between AV biofeedback and unguided CBCT images.
(5) Evaluation of the correlation between internal fiducial marker and external marker motion. With the internal and external respiratory signals acquired, how well these two motions correlate will be evaluated and whether AV biofeedback improves the correlation between internal and external respiratory motion. Internal motion will come from the motion of the fiducial markers, while external motion will be acquired from the the RPM system (i.e. motion of a marker block positioned on the patient's abdomen).
The correlation will be based on the displacement of internal/external motion with respect to time.
Timepoint [1] 300816 0
2 years after first recruitment

Eligibility
Key inclusion criteria
1) Liver cancer patients, either primary hepatocellular carcinoma or liver metastases, eligible for stereotactic radiotherapy
2) > 18 years old
3) No gender or ethnic restrictions
4) Radio-opaque markers implanted (fiducials and/or surgical clips previously implanted in the liver)
5) Ability to give written informed consent and willingness to participate and comply with the study
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1) Pregnant/ lactating women
2) <18 years old.
3) Prior radiotherapy treatment to the liver
4) Life expectancy less than 6 months
5) Non-liver cancer patients

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients fitting the eligibility criteria will be identified and introduced to this study by the treating physicians who will participate as investigators in this study.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/03/2013
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
30
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 470 0
Royal Prince Alfred Hospital - Camperdown

Funding & Sponsors
Funding source category [1] 286618 0
Government body
Name [1] 286618 0
NHMRC
Country [1] 286618 0
Australia
Primary sponsor type
University
Name
University of Sydney
Address
Sydney Medical School – Central
Room 475, Blackburn Building D06, Camperdown, NSW, 2006
Country
Australia
Secondary sponsor category [1] 285404 0
None
Name [1] 285404 0
Address [1] 285404 0
Country [1] 285404 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 288691 0
ERC
Ethics committee address [1] 288691 0
Ethics committee country [1] 288691 0
Australia
Date submitted for ethics approval [1] 288691 0
27/02/2013
Approval date [1] 288691 0
Ethics approval number [1] 288691 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 37170 0
Dr Regina Tse
Address 37170 0
Dept of Radiation Oncology, RPA Hospital, Missenden Road, Camperdown, NSW 2050, Australia
Country 37170 0
Australia
Phone 37170 0
(+612) 9515 8057
Fax 37170 0
Email 37170 0
[email protected]
Contact person for public queries
Name 37171 0
Carol Kwong
Address 37171 0
Dept of Radiation Oncology, RPA Hospital, Missenden Road, Camperdown. NSW. 2050
Country 37171 0
Australia
Phone 37171 0
(+612) 9515 6229
Fax 37171 0
Email 37171 0
[email protected]
Contact person for scientific queries
Name 37172 0
Sean Pollock
Address 37172 0
Foundation Building, 92-94 Parramatta Road. Camperdown. NSW. 2050
Country 37172 0
Australia
Phone 37172 0
(+61)404 759 239
Fax 37172 0
Email 37172 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseImpact of audiovisual biofeedback on interfraction respiratory motion reproducibility in liver cancer stereotactic body radiotherapy.2018https://dx.doi.org/10.1111/1754-9485.12702
N.B. These documents automatically identified may not have been verified by the study sponsor.